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Standard primary therapy for chronic graft-versus-host disease (GVHD) is incompletely effective. Based on
biologic insights implicating pathogenic B cells, we conducted a phase I trial examining the combination of
standard (1 mg/kg/day prednisone) glucocorticoid therapy with ofatumumab, a humanized anti-CD20
monoclonal antibody, for primary chronic GVHD therapy. Patients ages  18 with National Institutes of
Health Consensus moderate-to-severe chronic GVHD newly requiring 1 mg/kg/day prednisone were treated
at 3 escalating dose levels (300 mg, 700 mg, and 1000 mg) of i.v. ofatumumab on days 1 and 14 of initial
glucocorticoid therapy. Dose-limiting toxicity (DLT) was deﬁned by grade 4 infusion reactions, related grade 4
constitutional symptoms, related grade  3 organ toxicities, or grade 4 neutropenia lasting > 14 days. A total
of 12 patients (median age 54; range, 25 to 72) were treated (dose level 1: n ¼ 3; level 2: n ¼ 3; level 3: n ¼ 6).
At enrollment, overall chronic GVHD was moderate (n ¼ 7) or severe (n ¼ 5), with diverse organ involvement
(skin: n ¼ 8; mouth: n ¼ 8; eye: n ¼ 8; lung: n ¼ 4; gastrointestinal: n ¼ 3; liver: n ¼ 5; genital: n ¼ 2; joint/
fascia: n ¼ 5). Infusion of ofatumumab was well tolerated, and no DLT was observed. From the total number of
adverse events (n ¼ 29), possibly related adverse events (n ¼ 4) included grade 1 fatigue, grade 1 trans-
aminitis, and 2 infusion reactions (grades 2 and 3). Infectious complications were expected, and there were no
cases of hepatitis B reactivation or progressive multifocal leukoencephalopathy. Ofatumumab in combination
with prednisone is safe and a phase II examination of efﬁcacy is ongoing.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Chronic graft-versus-host disease (GVHD), a major late
complication of allogeneic hematopoietic cell trans-
plantation (HCT), is associated with mortality, disability,
infectious complications, prolonged immune suppression,
and impaired quality of life [1e8]. Accepted standard pri-
mary therapy for chronic GVHD includes  1 mg/kg/day of
prednisone with or without a calcineurin inhibitor [9,10]edgments on page 1081.
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ty for Blood and Marrow Transplantation.as combination therapy with other broadly immune sup-
pressive agents has not demonstrated consistent beneﬁt
over prednisone alone in controlled trials [11e13]. Only 30%
of patients will experience complete resolution of chronic
GVHD by 6 to 9 months of primary steroid therapy and
another 30% will achieve only a partial response [11e14].
Failure-free survival, deﬁned by absence of second-line im-
mune suppressive treatment, nonrelapse mortality (NRM),
and recurrent malignancy after initial systemic treatment
for chronic GVHD is only 68% at 6 months and 54% at 12
months [15].
Multiple observations support a role for B lymphocytes in
human chronic GVHD pathogenesis: B celleactivating factor
(BAFF) and the BAFF/B cell ratio have been associated with
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setting of established chronic GVHD, investigators have
detected antieH-Y in the setting of sex mismatched HCT
[17,18] and activating anti-platelet-derived growth factor
receptor (PDGFR) antibodies in the context of cutaneous
sclerosis [19]. Active chronic GVHD has been shown to
correlate with BAFF levels [20,21], BAFF/B cell ratio [22], as
well as various B cell subpopulations [22e27]. Interestingly,
several associations have also been detected with chronic
GVHD severity [26], phenotype [19,21,26], and response to
therapy [21,25,28]. Alongside these observations, anti-CD20
therapy in chronic GVHD has proven successful: rituximab
has demonstrated activity as a single-agent in steroid re-
fractory chronic GVHD [29]. As well, 2 independent trials
testing varied schedules of rituximab for chronic GVHD
prophylaxis after HCT have suggested improvements over
expected chronic GVHD rates [30,31].
Ofatumumab is a fully humanized IgG1kappamonoclonal
antibody (mAb) targeting a unique epitope on the CD20
molecule expressed on human B cells. As a type I CD20 mAb,
like rituximab, potent complement-dependent cytotoxicity
is dependent on ability to translocate CD20 into lipid rafts. In
contrast to rituximab, it has increased binding afﬁnity to
CD20, prolonged dissociation rate, and increased cell kill
(including B cells with low-density CD20 expression) due to
greater complement-dependent cytotoxicity [32e34].
Compared with rituximab and obinutuzumab, ofatumumab
demonstrates greater complement activation, independent
of CD20 density, and elicits the greatest monocyte-derived
macrophage mediated Ab-dependent cellular phagocytosis
[35]. Ofatumumab was approved for advanced chronic lym-
phocytic leukemia therapy in 2009 and has also demon-
strated activity in multiple lymphoid malignancies and
autoimmune conditions. Given experimental evidence of
increased potency, observations supporting activity in the
setting of prior rituximab exposure or rituximab resistance
[36e46] and evidence of chronic GVHD development after
rituximab prophylaxis [30,31], ofatumumab holds promise
as a novel chronic GVHD intervention.
The primary objective of the phase I component of this
phase I/II trial was to examine the safety of ofatumumab in
combination with 1 mg/kg/day prednisone as primary ther-
apy of chronic GVHD.
METHODS
Overview of Trial Design
The overall trial is a phase I/II trial to examine the safety and efﬁcacy of
prednisone and escalating dose of ofatumumab for primary therapy of
chronic GVHD (NCT01680965). Here we report the phase I trial results.
Phase II accrual is ongoing. Prednisone is uniformly initiated at 1 mg/kg/day
and the phase I component examined escalating dose of ofatumumab at
dose level cohorts of 300mg, 700mg, and 1000mg given on days 0 and 14 of
study. In the phase II component, patients are followed for 24 months
(baseline, study therapy day 0 and day 14, and months 1, 3, 6, 12, 18, and 24
after therapy). The primary efﬁcacy endpoint for the phase II trial is 6-month
clinician-reported overall response (composite of complete and partial
response). Additional endpoints include other therapeutic responsemetrics,
utilization of second-line systemic immune suppressive therapy, additional
clinical and patient-reported outcomes, and allied biologic correlative
studies.
Included Patients
Adults ages  18 with chronic GVHD newly requiring systemic gluco-
corticoid therapy were included. Chronic GVHD diagnosis and severity
scoring adhered to the National Institutes of Health (NIH) Consensus Criteria
on Diagnosis and Staging of Chronic GVHD [47]. In the phase I component of
this trial, only those with overall moderate-to-severe chronic GVHD were
eligible. Patients had to begin ofatumumab therapy within 14 days from
initiation of 1 mg/kg/day of prednisone therapy for chronic GVHD. Thefollowing were study exclusion criteria: relapsed malignancy after HCT,
previous systemic glucocorticoid therapy at 1 mg/kg/day prednisone or
equivalent for chronic GVHD, current hepatic/biliary disease (with exception
of that due to chronic GVHD), treatment with experimental noneFood and
Drug Administrationeapproved therapy within 5 terminal half-lives or 4
weeks before enrollment, other solid tumor within past 5 years (except
completely resected nonmelanoma skin cancer), prior treatment with any
anti-CD20 monoclonal antibody or alemtuzumab within 3 months, uncon-
trolled infectious complications, signiﬁcant cerebrovascular disease in past 6
months, human immunodeﬁciency virus positivity, uncontrolled signiﬁcant
cardiac or other medical conditions, clinically active hepatitis B deﬁned as
positive HBsAg or positive HBcAb with detectable hepatitis B viral load,
active hepatitis C conﬁrmed by viral load, pregnancy or lactation, women
and men unable or unwilling to use adequate contraceptive methods
through 1 year after completion of protocol therapy, absolute neutrophil
count < 1.0  109/L; creatinine > 2  upper limit of normal (ULN), total
bilirubin > 1.5  ULN, transaminase > 2  ULN, or alkaline phosphatase >
2.5  ULN (except for that due to chronic GVHD).
Treatment Plan
Prednisone was started at 1 mg/kg actual body weight per day. The
duration of prednisone therapy and tapering schedule were not mandated
by the protocol. In the setting of increased chronic GVHD activity, predni-
sone could be increased with upper limit of 1 to 2 mg/kg/day; doses higher
than this were considered a separate line of additional systemic immune
suppressive therapy. As no cases had discontinued all systemic immune
suppression (both initial GVHD prophylaxis agents and any therapy deliv-
ered for acute GVHD) by the time of chronic GVHD onset, these agents were
continued alongside the new addition of study therapy (1 mg/kg/day
prednisone þ ofatumumab). Taper of other systemic agents and use of
topical agents (eg, ocular drops, mouth rinses, topical steroid creams) were
not regulated by the trial. Ofatumumab was administered by i.v. infusion;
preparation and infusion conditions were per standard procedures. Dose
level cohorts in this phase I trial included the following: cohort 1, 300 mg;
cohort 2, 700 mg; and cohort 3, 1000 mg (all delivered once on day 0 and
again on day 14 of therapy). This dose/schedule was modeled after a prior
trial conducted in rheumatoid arthritis that demonstrated safety, sustained
depletion of peripheral blood CD19þ B cells (persistent for 48 weeks), and
efﬁcacy with association between increasing dose and clinical response [48].
A dose level1 of 100mgwas prespeciﬁed in the event excess dose-limiting
toxicity (DLT) occurred at dose level 1. Premedication was uniformly deliv-
ered within 30 minutes before each infusion: acetaminophen 1000 mg,
diphenhydramine 50 mg, and methylprednisolone i.v. 50 mg. Vital signs
were monitored every 30 (5) minutes during infusion or more frequently
as needed. The initial infusion rate, timing of sequential infusion rate
escalation, and rules surrounding response to observed infusion reactions
were enforced. If grade 4 infusion reactions occurred, no further ofatumu-
mab therapy was to be given; lesser grade infusion reactions were managed
with supportive care including i.v. ﬂuids, antihistamines, and steroids.
Supportive antimicrobial prophylaxis followed institutional standards.
Immunoglobulin replacement was delivered per discretion of the treating
physician, not mandated per protocol.
Phase I Trial Characteristics
The phase I trial followed a traditional (3 þ 3) escalation design. Suc-
cessive dose level cohorts were enrolled and monitored for DLT. The mini-
mum DLT observation period was 46 days after completion of ofatumumab
therapy for the last patient on each dose level. DLT was deﬁned by the
occurrence of any of the following within 46 days of the last ofatumumab
therapy: grade 4 infusion reactions, grade 4 constitutional symptoms at least
possibly due to ofatumumab,  grade 3 organ toxicities at least possibly due
to ofatumumab, and grade 4 neutropenia lasting more than 14 days. The
following were criteria for patient termination from the study: patient
withdrawal, death, relapsedmalignancy, and completion of study follow-up.
Patients in the maximally tolerated dose (MTD) cohort are carried forward
in the phase II component and will complete all planned phase II follow-up
(24 months), whereas those at lower non-MTD cohorts complete an
abbreviated study follow-up with clinical assessment measures and biologic
studies only at the 6- and 12-month time points.
Statistical Methods
The occurrence of DLT attributable to ofatumumab in17% served as the
boundary for the MTD of ofatumumab in this phase I trial. Escalation to each
higher dose level was permitted when 0 of 3 or nomore than 1 of 6 (number
treated per level was increased to 6 if 1 of 3 experienced a DLT) in a dose
level cohort experienced a DLT. Dose de-escalationwas indicated if a greater
proportion experienced a DLT at any dose level. A total of 6 patients were
enrolled at the MTD cohort.
Table 2
Chronic GVHD Characteristics at Initiation of Therapy
Variable Frequency (%)
NIH Consensus 0-3 Scores NIH 0 NIH 1 NIH 2 NIH 3
Skin 4 (33%) 2 (17%) 5 (42%) 1 (8%)
Mouth 4 (33%) 6 (50%) 2 (17%) 0
Eye 4 (33%) 5 (42%) 2 (17%) 1 (8%)
Lung 8 (67%) 2 (17%) 2 (17%) 0
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in NIH 0 to 3 chronic GVHD severity (per organ sites and overall), as well
as clinician-reported overall responses (complete response [CR],
partial response [PR], stable disease [SD], progressive disease [PD]). These
clinician-reported responses are reported in the following ways: (1) as re-
ported, (2) with response category changed to PD for addition of a new line
of systemic immune suppressive therapy beyond ﬁrst-line prednisone þ
ofatumumab, and (3) both to account for new systemic therapy and for new
topical agents not present before study enrollment.GI 9 (75%) 2 (17%) 1 (8%) 0
Liver 7 (58%) 4 (33%) 0 1 (8%)
Genital 10 (83%) 2 (17%) 0 0
Joint/fascia 7 (58%) 2 (17%) 2 (17%) 1 (8%)
Overall 0 0 7 (58%) 5 (42%)
Chronic GVHD onset type
De novo 3 (25%)
Interrupted 7 (58%)
Progressive 2 (17%)
Chronic GVHD subtype
Classic 5 (42%)
Overlap 7 (58%)
HCT-CI (at trial
enrollment) [49]
<3 2 (17%)
3 10 (83%)
KPSData and Safety Monitoring
A comprehensive data and safety monitoring plan adhered with the
standard procedures of the H. Lee Mofﬁtt Cancer Center and Research
Institute. The trial was conducted with the approval of the University of
South Florida institutional review board. The study principal investigator
and allied study team members monitored toxicity, and reported adverse
(AE) and serious adverse events (scored per Common Terminology Criteria
for Adverse Events version 4.0) to the institutional review board, the Mofﬁtt
Protocol Monitoring Committee, and the US Food and Drug Administration.
All AEs (grades 1 to 5) were collected within 24 hours of start of ofatumu-
mab infusion, grade 3 to 5 AE were collected within 60 days, and only AE
deemed related to the investigational therapy were collected beyond day 61.
Additional monitoring was employed for hepatic function, screening for
hepatitis B reactivation, development of progressive multifocal leukoence-
phalopathy (PML), and pregnancy.<90 4 (33%)
90 8 (67%)
Platelet count, median
(range), k/uL
164 (92-287)
Bilirubin, mg/dL .6 (.2-.9)
Two-minute walk test,
median (range), feet [50]
480 (140-574)
Baseline systemic immune
suppression
Sirolimus 8 (67%)
Tacrolimus 10 (83%)
Prednisone (range, .14-.5
mg/kg daily dose)
3 (25%)
ECP 1 (8%)
FAM 2 (17%)RESULTS
Baseline Patient and Chronic GVHD Characteristics
Twelve patients in total were treated on the phase I trial,
including 3 on dose level 1 (300 mg), 3 on dose level 2 (700
mg), and 6 total on dose level 3 (1000 mg). A patient ﬂow
diagram is presented as Supplemental Figure 1. Patient
characteristics are summarized in Table 1. Hematologic ma-
lignancies serving as HCT indication were diverse, and none
had evidence of relapse/progression at time of study
enrollment. HCT were from both sibling and unrelated do-
nors and were predominantly peripheral blood mobilizedTable 1
Baseline Patient Characteristics
Variable Frequency (%)
Age, median (range), yr 54 (25-72)
Donor age, median (range), yr 29 (24-56)
Donor/recipient gender
Female/male 1
Others 11
Race
White/Caucasian 12 (100%)
Disease category
ALL 4 (33%)
AML 2 (17%)
CLL 1 (8%)
CMML 1 (8%)
IMF 1 (8%)
MCL 1 (8%)
MDS 2 (17%)
Remission status at transplantation
CR 8 (67%)
HI 2 (17%)
PR 2 (17%)
Graft source
BM 1 (8%)
PBSC 11 (92%)
Donor type
Matched sibling 4
Matched unrelated 8
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leu-
kemia; CLL, chronic lymphocytic leukemia; CMML, chronic myelomonocytic
leukemia; IMF, idiopathic myeloﬁbrosis; MCL, mantle cell lymphoma; MDS,
myelodysplastic syndrome; HI, hematologic improvement; BM, bone
marrow; PBSC, peripheral blood mobilized stem cells.
Data presented are n (%) unless otherwise indicated.
Baseline topical immune
suppression
Beclomethasone (GI) 1 (8%)
Budesonide (GI) 2 (17%)
Triamcinolone (skin) 2 (17%)
Dexamethasone (mouth) 4 (33%)
Tacrolimus (skin) 1 (8%)
GI indicates gastrointestinal; HCT-CI, HCT comorbidity index; KPS, Karnof-
sky performance status; ECP, extracorporeal photopheresis; FAM, combi-
nation therapy with ﬂuticasone, azithromycin, monteleukast.grafts. Female donor/male recipient gender pairing was
infrequent.
Chronic GVHD characteristics at study enrollment are
presented in Table 2. All cases had an overall global NIH 0 to 3
score of moderate-to-severe (2 and 3). Skin, mouth, and eye
involvement were most common. All cases had multiple
organ sites concurrently involved at therapy initiation, the
majority had overlap subtype of chronic GVHD, andmost had
previously manifested acute GVHD. We note that the organ
involvement represented here is a reﬂection of the enrolled
patients’ heterogeneous chronic GVHD involvement, not an
accurate population-based estimate of frequency of organs
involved in incident chronic GVHD. Poor performance status,
bilirubin elevation, and thrombocytopenia were infrequent.
In keeping with institutional practices, the majority were
on primary immune suppression prophylaxis, including
tacrolimus and sirolimus at the time of chronic GVHD
development and enrollment on trial. Other systemically
active immune suppressive agents represented at study
enrollment (prednisone, extracorporeal photopheresis) were
on taper from prior acute GVHD therapy. Two cases with
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thromycin, and monteleukast therapy. Baseline topical
agents are listed in Table 2.Study Therapy: Ofatumumab Infusion and Prednisone
Taper
Ofatumumab infusion was well tolerated. The median
time required for completion of baseline and day 14 infusions
were 5 (range, 4 to 10) and 4 (range, 4 to 9) hours, respec-
tively. Two infusion reactions (grades 2 and 3) occurred and
resolvedwith supportive care, and all patients completed the
full planned study therapy. Prednisonewas uniformly started
at 1 mg/kg/day and then tapered according to the treating
clinician’s discretion. As demonstrated in Figure 1, the actual
prednisone taper was rapid. The median prednisone dose
was .4 (range, .1 to .8) mg/kg/day at 1 month, .1 (range, 0 to
.4) mg/kg/day at 3 months, and .07 (range, 0 to .3) at 6
months. These data correspond to a large percentage
reduction from starting prednisone dose at 3 (median, 89%;
range 57% to 100%) and 6months (median, 93%; range, 71% to
100%). Whereas systemic immune suppression present
before chronic GVHD onset and trial enrollment (ie, those
agents still present from primary prophylaxis and acute
GVHD therapy) was not regulated on this trial, none of these
baseline immune suppressive agents (Table 2) were dis-
continued during the study follow-up.
Additional systemic therapy beyond prednisone within 6
months was only used in 1 case: mycophenolate mofetil
(MMF) was started 28 days after study therapy initiation for
rising liver function tests. Three patients were treated with
new topical agents after study enrollment: 1 patient newly
received cyclosporine ophthalmic emulsion (Restasis) at day
14, topical triamcinolone (skin) at 3.7 months, and oral
azathioprine at 14.2 months. A second patient started topical
triamcinolone (skin) at 33 days. The ﬁnal patient started
cyclosporine ophthalmic emulsion (Restasis, Allergan, Irvine,
CA) at 5.3 months.Safety: DLT, AE, and Infectious Complications
No cases of grade 4 infusion reactions, related grade 4
constitutional symptoms, related grade  3 organ toxicities,
or grade 4 neutropenia lasting > 14 days were observed, andFigure 1. Reduction in systemic glucocorticoid therapy during study period.
Box plots present median values and whiskers present minimum-maximum
range.hence no DLT events occurred throughout the study. Three
patients each were treated on dose levels 1 and 2 (300 mg,
700 mg), and 6 patients were treated on dose level 3 (1000
mg), which was therefore deﬁned as the recommended
phase II dose. All AE on trial, regardless of attribution to
ofatumumab therapy, are listed in Table 3. From 29 total
adverse events, 4 were deemed possibly related to ofatu-
muab, including the above-mentioned 2 infusion reactions,
as well as 1 event each of grade 1 fatigue and grade 1
transaminase elevation. Other observed AE were largely ex-
pected complications of high-dose prednisone therapy. One
patient with severe bronchiolitis obliterans had multiple
events, including recurrent pulmonary infections, hospitali-
zations, dyspnea, and hypoxia, consistent with the natural
history of this disease. There were no cases of hepatitis B
reactivation or PML. All infections noted on trial are
described in Table 4.
Preliminary Assessment of Efﬁcacy and Biologic Activity
Change in NIH global 0 to 3 scores and clinician-reported
response assessments are presented in Figure 2. Responses
were seen in moderate and severe chronic GVHD, across
individual organ sites (Supplemental Table 1), and in both
classic and overlap subtypes of chronic GVHD. Clinician-
reported responses for evaluable patients (3-month CR/PR
rate ¼ 11 of 12, consisting of CR 2, PR 9, and SD 1; 6-month
CR/PR rate ¼ 8 of 10, consisting of CR 4, PR 4, and SD 2)
were favorable. Two patients were not eligible for response
assessment at 6 months (death: n ¼ 1, inadequate follow-up
time: n ¼ 1).
Response rates accounting for additional systemic im-
mune suppressive therapy are the following: 1 patient
received MMF for liver function test (LFT) elevation before 3-
month assessment and, thus, would be considered PD. Thus,
3-month CR/PR rate would be 10 of 12 (consisting of CR 2, PR
8, SD 1, and PD 1) and 6-month CR/PR would be 8 of 11
(consisting of CR 4, PR 4, SD 2, and PD 1)dthis patient lacks
6-month follow-up currently but would contribute to the
total denominator at 6 months and count as failure based on
early addition of MMF.
Response rates accounting for both additional systemic
and topical agents are the following: accounting for both
additional systemic and topical agents added after study
enrollment (eliminating response assessment at organ sites
for which new topical agents were added, except for
permitting assessment of progressive disease), the above
response rates would change in the following manner: 3-
month response would be unaltered (CR/PR ¼ 10 of 12,
consisting of CR 2, PR 8, SD 1, and PD 1), whereas 6-month
response (CR/PR ¼ 7 of 11, consisting of CR 4, PR 3, SD 2,
and PD 2) would decrease because of the addition of topical
Restasis for ocular symptoms not present at baseline (despite
response in other multiple organs involved). In the other 2
cases of new topical agents added, these were implemented
for existing organ involvement at baseline; silencing
response assessment in organs targeted by these topical
agents did not alter response category due to responsive
disease in other sites and no progression in any sites.
Serial measures of immune globulin and lymphocyte
subsets are presented in Figure 3. Therapy was associated
with signiﬁcant reduction in total CD19þ B cells. No signiﬁ-
cant differences were observed for these parameters ac-
cording to ofatumumab dose level. No malignancy relapse
was seen on trial. The median follow-up time for surviving
patients is currently 13 months (range, 6 to 24 months). Two
Table 3
Summary of Adverse Events
Toxicity Category Description (Toxicity Type Code) Grade 1
n (%)
Grade 2
n (%)
Grade 3
n (%)
Grade 4
n (%)
All n (%) n
Eye disorders Blurred vision - 1 (8.3) - - 1 (8.3) 12
GI disorders GI disorders-other, specify (gastritis) 1 (8.3) - - - 1 (8.3) 12
General disorders and administration
site conditions
Edema limbs 1 (8.3) - - - 1 (8.3) 12
Fatigue 1 (8.3) - - - 1 (8.3) 12
Infusion-related reaction - 1 (8.3) 1 (8.3) - 2 (16.7) 12
Infections and infestations Infections and infestations - other,
specify (surgical site infection after surgery)
- - 1 (8.3) - 1 (8.3) 12
Lung infection - 1 (8.3) - 1 (8.3) 2 (16.7) 12
Nail infection - 1 (8.3) - - 1 (8.3) 12
Skin infection - 1 (8.3) - - 1 (8.3) 12
Upper respiratory infection - 1 (8.3) 1 (8.3) - 2 (16.7) 12
Injury, poisoning, and
procedural complications
Bruising 1 (8.3) - - - 1 (8.3) 12
Investigations Aspartate aminotransferase increased 1 (8.3) - - - 1 (8.3) 12
Metabolism and nutrition disorders Hyperglycemia - - 1 (8.3) - 1 (8.3) 12
Musculoskeletal and
connective tissue disorders
Arthralgia - 1 (8.3) - - 1 (8.3) 12
Chest wall pain - - 1 (8.3) - 1 (8.3) 12
Musculoskeletal and connective tissue
disorder - other, specify (hand/foot cramping)
- 1 (8.3) - - 1 (8.3) 12
Muscle weakness lower limb 1 (8.3) - - - 1 (8.3) 12
Musculoskeletal and connective
tissue disorder - other, specify (fall)
- - 1 (8.3) - 1 (8.3) 12
Nervous system disorders Facial nerve disorder - 1 (8.3) - - 1 (8.3) 12
Peripheral motor neuropathy - 1 (8.3) - - 1 (8.3) 12
Peripheral sensory neuropathy - 1 (8.3) - - 1 (8.3) 12
Tremor - 1 (8.3) - - 1 (8.3) 12
Psychiatric disorders Insomnia - - 1 (8.3) - 1 (8.3) 12
Respiratory, thoracic, and
mediastinal disorders
Dyspnea 1 (8.3) - 1 (8.3) - 2 (16.7) 12
Hypoxia - - 1 (8.3) - 1 (8.3) 12
Overall (total AE, % grade AE
per total number of AE)
All 7 (24%) 12 (41%) 9 (31%) 1 (3%) 29
Individual AE (per CTCAE version 4.0) observed on trial from time of treatment initiation through complete study follow-up to date. Individual AE are presented
with percent of total (n ¼ 12) patients with each AE.
Total AE per AE grade are presented with percent of total number of AE observed. AE deemed possibly related to ofatumumab therapy are in bold (n ¼ 4, or 14%
of total AE)
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obliterans (n ¼ 1) complicated by recurrent infections at 11
months after therapy onset, and aspiration pneumonia (n ¼
1) in a deconditioned patient undergoing rehabilitation at 79
days), and were not deemed related to study therapy.
DISCUSSION
Given limited efﬁcacy of currently available chronic GVHD
primary treatment strategies, novel approaches are needed.Table 4
Summary of Infectious Complications on Trial
Site Organism Day Grade
Nasopharynx Rhinovirus* 4 3
Rhinovirus 78 1
Rhinovirus 34 2
Oral Candida 14 2
Pulmonary/BAL CMV* 3
Pseudomonas* 5 3
MAI* 5 3
MRSA 83 2
Surgical site CNS 27 3
Blood CMV 20 2
Day indicates number of days following initiation of study therapy; BAL,
bronchoalveolar lavage; CMV, cytomegalovirus; MAI, mycobacterium
avium intracellulare; MRSA, methicillin-resistant staphylococcus aureus;
CNS, coagulase-negative staphylococcus.
* Denotes multiple infectious complications experienced by 1 individual
patient with bronchiolitis obliterans syndrome. All other identiﬁed in-
fections were single events in individual patients.Based on extensive evidence implicating B cells in chronic
GVHD pathobiology, we tested ofatumumab, a highly potent
humanized anti-CD20 monoclonal antibody, together with
standard 1 mg/kg/day prednisone as initial therapy for NIH
moderate-to-severe chronic GVHD in a phase I/II trial. The
central aim of the phase I component of this trial was to
establish the safety of this approach.
The phase I dose escalation was modeled after a prior
study in rheumatoid arthritis, as this dose/schedule
demonstrated safety, clinical efﬁcacy, and profound sus-
tained B cell depletion [48]. Our data support the safety of
this approach in primary therapy of chronic GVHD: no DLT
was observed. Thus, escalation proceeded to the planned
maximal dose level, which was deﬁned as the recommended
phase II dose. All patients completed planned study therapy,
and only 2 infusion reactions occurred among the 12 treated.
Infusional toxicity of ofatumumab was modest, and the 2
observed reactions were treated to resolution with sup-
portive care. Additionally, the observed AE on trial were
largely expected complications of intensive prednisone
therapy. Importantly, the additional immune suppression
induced by profound B cell depletion in the setting of pred-
nisone therapy raises concern for potential increase in risk.
The data, however, provide no signal of excess infectious
morbidity, compared with that previously reported in
chronic GVHD initial therapy [13], or NRM. Importantly, we
also observed no cases of viral hepatitis reactivation or PML.
Although the total number on this phase I study limits
Figure 2. Change in chronic GVHD severity. (A) Indicates distribution of NIH global 0 to 3 scores at baseline, 3 months, and 6 months. (B) Indicates change in global
NIH 0 to 3 score from baseline to 6 months separately for those with initial score 2 (top) versus 3 (bottom). (C) Indicates clinician-reported overall response category
at 3 months (top) and 6 (bottom) months.
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GVHD cohorts, the observed survival is encouraging, partic-
ularly given the higher risk characteristics (exclusively
moderate-to-severe chronic GVHD [1], predominance of
overlap subtype [51], presence of lung involvement [52],
increased chronic GVHD HCT comorbidity index [53] of the
study patients.Although the phase I component of this trial is not
adequately powered to address efﬁcacy, we note that therapy
was associated with encouraging response rates at 3 and 6
months, both according to clinician-assessed overall
response categories and according to change in NIH 0 to 3
chronic GHVD severity scores. Only 1 patient required an
additional line of systemic immune suppressive therapy
Figure 3. Ofatumumab therapy depletes total CD19þ B cells and IgG.
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up, and use of additional topical agents was limited.
Although speciﬁc comparisons are limited, responses were
seen in both moderate and severe chronic GVHD, across
varied sites of organ involvement, and in both classic and
overlap subtype. As a surrogate of effective chronic GVHD
control, major reduction in prednisone dose was achieved by
3 and 6 months of therapy. Further conclusions regarding
efﬁcacy will be made after completion of the phase II
component of the trial.
We acknowledge the existing studies examining the
impact of rituximab-based interventions in refractory
chronic GVHD therapy [29], primary chronic GVHD therapy
together with prednisone [54], and also as chronic GVHD
prophylaxis [30,31]. These and allied correlative science have
laid an important foundation for B cell depletion strategies in
chronic GVHD interventional trials. However, the following
speak to the need for ongoing progress: rituximab appears tooffer incomplete protection from chronic GVHD as evidenced
by chronic GVHD in that setting [30], failure of initial com-
bined therapy or escape associated with resurgence of H-Y
antibodies has been noted [54], and therapy in more
advanced chronic GVHDdalthough certainly activedis
incompletely effective [29,55]. These shortcomings, taken
together with clinical observations and mechanistic insight
suggesting greater potency of ofatumumab, support the
rationale to study ofatumumab in chronic GVHD therapy.
Mature results from the phase II trial, with particular atten-
tion to chronic GVHD characteristics and detailed response
assessment, will facilitate an assessment of comparative
efﬁcacy.
We note the following limitations: whereas the phase I
trial established the MTD and the observed safety proﬁle is
reassuring, additional and longer-term safety data will be
generated through the phase II component of this trial.
Additionally, more complete efﬁcacy assessment, including
J. Pidala et al. / Biol Blood Marrow Transplant 21 (2015) 1074e1082 1081detailed examination of competing proposed response as-
sessments and association with subsequent outcomes
including treatment failure and failure-free survival, will
only be possible in the phase II setting. As well, we note that
taper of prednisone and thresholds for invoking either new
topical or systemic immune suppressive agents on trial can’t
be mandated, and, thus, are subject to individual clinician’s
judgment; this reality complicates analysis but is not a
challenge unique to this trial. Finally, we note that the cur-
rent report of immune populations and immunoglobulins
provides only initial biologic insight; more detailed studies
and predictive biomarker analyses are planned for the
complete phase II trial.
In summary, the addition of ofatumumab at 1000 mg at
days 0 and 14 of initial 1 mg/kg/day prednisone therapy for
NIHmoderate-to-severe chronic GVHD is safe and associated
with favorable clinical responses and reduction in
prednisone.
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